Adhesion molecules and cardiovascular risk in peripheral arterial disease

Summary

Although intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) play a relevant role in atherosclerosis, little is known about the prognostic impact of their soluble forms (s) in patients with peripheral arterial disease (PAD). The aim of this prospective study was to verify whether plasma levels of s ICAM-1 and s VCAM-1 predict cardiovascular risk in PAD, and improve the prognostic value of the ankle/brachial index (ABI) alone. Accordingly, plasma levels of sICAM-1 and sVCAM-1, and the ABI were measured in 75 PAD patients who were monitored for a mean of 24±13 months. Twenty-two (29.3%) patients had a cardiovascular event (15 coronary, 3 cerebrovascular and 4 peripheral events). Plasma levels of sVCAM-1 were 618±258 ng/mL in patients with and 496±164 ng/mL in those without an event (p= 0.016). The corresponding sICAM-1 values were 344±239 ng/mL and 275±99 ng/mL (p= 0.079). The cardiovascular event rate was higher in patients with sVCAM-1 levels above the median than in those with sVCAM-1 below the median (p=0.0027 by log rank test). Independent predictors of events were sVCAM-1 levels above the median (p=0.005) and an ABI below the median (p= 0.001). Amongst patients with ABI below the median, the occurrence of sVCAM-1 above the median was associated with a 3.4-fold increase in risk (95% CI 1.308 to 9.573, p= 0.013). In conclusion, increased plasma levels of sVCAM-1 have a negative prognostic impact in PAD and improve the predictive value of ABI, which is currently the most powerful risk indicator in these patients.

Keywords

Peripheral arterial disease - adhesion molecules - cardiovascular diseases - prognosis - risk prediction

^* These authors contributed equally to the paper

• References

• 1 Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203.
• 2 Cybulsky M, Gimbrone M. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251: 788-91.
• 3 Iiyama K, Hajra L, Iiyama M. et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res 1999; 85: 199-207.
• 4 Davies M, Gordon J, Gearing A. et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 1993; 171: 223-9.
• 5 Ridker PM, Hennekens CH, Roitman-Johnson B. et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92.
• 6 Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
• 7 Blankenberg S, Rupprecht HJ, Bickel C. et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104: 1336-42.
• 8 Mulvihill NT, Foley JB, Murphy RT. et al. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart 2001; 85: 623-7.
• 9 Blann AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost 1994; 72: 151-4.
• 10 Brevetti G, Martone VD, de Cristofaro T. et al. High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilation in patients with peripheral arterial disease. Thromb Haemost 2001; 85: 63-6.
• 11 Brevetti G, Piscione F, Silvestro A. et al. Increased inflammatory status and higher prevalence of threevessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. Thromb Haemost 2003; 89: 1058-63.
• 12 Blann AD, Seigneur M, Steiner M. et al. Circulating ICAM-1 and VCAM-1 in peripheral artery disease and hypercholesterolemia: relationship to the location of atherosclerotic disease, smoking, and in the prediction of adverse events. Thromb Haemost 1998; 79: 1080-5.
• 13 Brevetti G, Martone V, Perna S. et al. Intermittent claudication and risk of cardiovascular event. Angiology 1998; 49: 843-8.
• 14 Criqui MH, Langer RD, Fronek A. et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-6.
• 15 McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991; 87: 119-28.
• 16 Peter K, Nawroth P, Conradt C. et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 1997; 17: 505-12.
• 17 Silvestro A, Scopacasa F, Ruocco A. et al. Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease. Vasc Med 2003; 8: 225-32.
• 18 Brevetti G, Silvestro A, Schiano V. et al. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003; 108: 2093-8.
• 19 Newman A, Sutton-Tyrrell K, Vogt M. et al. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA 1993; 270: 487-9.
• 20 Cox D. Regression and life tables. J R Stat Soc 1972; 34: 187-220.
• 21 Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-12.
• 22 Ohta T, Saku K, Takata K. et al. Soluble vascular cell-adhesion molecule-1 and soluble intercellular adhesion molecule-1 correlate with lipid and apolipoprotein risk factors for coronary artery disease in children. Eur J Pediatr 1999; 158: 592-8.
• 23 Corretti MC, Anderson TJ, Benjamin EJ. et al. Guidelines for the ultrasound assessment of endothelial- dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65.
• 24 O'Brien KD, McDonald TO, Chait A. et al. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996; 93: 672-82.
• 25 Li H, Cybulsky M, Gimbrone MJ. et al. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leucocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 1993; 13: 197-204.
• 26 O'Riordain D, O'Donnell J. Realistic expectations for the patient with intermittent claudication. Br J Surg 1991; 78: 861-2.
• 27 Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994; 1: 333-9.
• 28 Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 2002; 106: 820-5.
• 29 Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-9.
• 30 Maresca G, Di Blasio A, Marchioli R. et al. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999; 19: 1368-77.
• 31 Gokce N, Keaney , Jr. JF, Hunter LM. et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003; 41: 1769-75.
• 32 Rasmussen L, Hansen P, Nabipour M. et al. Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl- CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem J 2001; 360: 363-70.
• 33 Cominacini L, Pasini A, Garbin U. et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 2002; 15: 891-5.
• 34 Fenster BE, Tsao PS, Rockson SG. Endothelial dysfunction: clinical strategies for treating oxidant stress. Am Heart J 2003; 146: 218-26.
• 35 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
• 36 The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.